IBDEI0QK ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13107,1,4,0)
 ;;=4^V16.41
 ;;^UTILITY(U,$J,358.3,13107,1,5,0)
 ;;=5^Family h/o Cancer of Ovary
 ;;^UTILITY(U,$J,358.3,13107,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,13108,0)
 ;;=V16.42^^87^830^16
 ;;^UTILITY(U,$J,358.3,13108,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13108,1,4,0)
 ;;=4^V16.42
 ;;^UTILITY(U,$J,358.3,13108,1,5,0)
 ;;=5^Family h/o Cancer of Prostate
 ;;^UTILITY(U,$J,358.3,13108,2)
 ;;=^317952
 ;;^UTILITY(U,$J,358.3,13109,0)
 ;;=V16.43^^87^830^17
 ;;^UTILITY(U,$J,358.3,13109,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13109,1,4,0)
 ;;=4^V16.43
 ;;^UTILITY(U,$J,358.3,13109,1,5,0)
 ;;=5^Family h/o Cancer of Testis
 ;;^UTILITY(U,$J,358.3,13109,2)
 ;;=^317953
 ;;^UTILITY(U,$J,358.3,13110,0)
 ;;=V19.5^^87^830^19
 ;;^UTILITY(U,$J,358.3,13110,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13110,1,4,0)
 ;;=4^V19.5
 ;;^UTILITY(U,$J,358.3,13110,1,5,0)
 ;;=5^Family h/o Congenital Anomalies
 ;;^UTILITY(U,$J,358.3,13110,2)
 ;;=^295325
 ;;^UTILITY(U,$J,358.3,13111,0)
 ;;=V19.2^^87^830^20
 ;;^UTILITY(U,$J,358.3,13111,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13111,1,4,0)
 ;;=4^V19.2
 ;;^UTILITY(U,$J,358.3,13111,1,5,0)
 ;;=5^Family h/o Deafness Or Hearing Loss
 ;;^UTILITY(U,$J,358.3,13111,2)
 ;;=^295322
 ;;^UTILITY(U,$J,358.3,13112,0)
 ;;=V17.3^^87^830^23
 ;;^UTILITY(U,$J,358.3,13112,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13112,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,13112,1,5,0)
 ;;=5^Family h/o Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,13112,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,13113,0)
 ;;=V16.6^^87^830^24
 ;;^UTILITY(U,$J,358.3,13113,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13113,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,13113,1,5,0)
 ;;=5^Family h/o Leukemia
 ;;^UTILITY(U,$J,358.3,13113,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,13114,0)
 ;;=V18.61^^87^830^27
 ;;^UTILITY(U,$J,358.3,13114,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13114,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,13114,1,5,0)
 ;;=5^Family h/o Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,13114,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,13115,0)
 ;;=V17.0^^87^830^28
 ;;^UTILITY(U,$J,358.3,13115,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13115,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,13115,1,5,0)
 ;;=5^Family h/o Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,13115,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,13116,0)
 ;;=V19.4^^87^830^29
 ;;^UTILITY(U,$J,358.3,13116,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13116,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,13116,1,5,0)
 ;;=5^Family h/o Skin Condition
 ;;^UTILITY(U,$J,358.3,13116,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,13117,0)
 ;;=V17.1^^87^830^30
 ;;^UTILITY(U,$J,358.3,13117,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13117,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,13117,1,5,0)
 ;;=5^Family h/o Stroke (Cerebrovascular)
 ;;^UTILITY(U,$J,358.3,13117,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,13118,0)
 ;;=V16.8^^87^830^26
 ;;^UTILITY(U,$J,358.3,13118,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13118,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,13118,1,5,0)
 ;;=5^Family h/o Other Specified Cancer
 ;;^UTILITY(U,$J,358.3,13118,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,13119,0)
 ;;=V11.1^^87^830^35
 ;;^UTILITY(U,$J,358.3,13119,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13119,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,13119,1,5,0)
 ;;=5^Personal h/o Affective Disorder
 ;;^UTILITY(U,$J,358.3,13119,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,13120,0)
 ;;=V15.89^^87^830^49
 ;;^UTILITY(U,$J,358.3,13120,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13120,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,13120,1,5,0)
 ;;=5^Personal h/o Exposure To Persian Gulf Region
